Search

Your search keyword '"Guarena, C"' showing total 91 results
Start Over Author "Guarena, C"
91 results on '"Guarena, C"'

11. Quiz page. Acute infarction in a grafted kidney

Author

Piccoli, Giorgina Barbara, Burdese, M, Rossetti, M, Savio, D, Suriani, C, Guarena, C, Consiglio, V, Mezza, E, Soragna, G, Rabbia, C, Segoloni, Giuseppe, and Piccoli, G.

Subjects
Male, Reoperation, Hypertension, Renovascular, Postoperative Complications, Infarction, Humans, Thrombosis, Middle Aged, Kidney, Tomography, X-Ray Computed, Kidney Transplantation, Magnetic Resonance Imaging, Abdominal Pain
Published
2005

12. AKI - human studies

Author

Kutlay, S., primary, Kurultak, I., additional, Nergizoglu, G., additional, Erturk, S., additional, Karatan, O., additional, Azevedo, P., additional, Pinto, C. T., additional, Pereira, C. M., additional, Marinho, A., additional, Vanmassenhove, J., additional, Hoste, E., additional, Glorieux, G., additional, Dhondt, A., additional, Vanholder, R., additional, Van Biesen, W., additional, Rei, S., additional, Aleksandrova, I., additional, Kiselev, V., additional, Ilynskiy, M., additional, Berdnikov, G., additional, Marchenkova, L., additional, Daher, E. F., additional, Vieira, A. P. F., additional, Souza, J. B., additional, Falcao, F. S., additional, Costa, C. R., additional, Fernandes, A. A. C. S., additional, Mota, R. M. S., additional, Lima, R. S. A., additional, Silva Junior, G. B., additional, Ulusal Okyay, G., additional, Erten, Y., additional, Er, R., additional, Aybar, M., additional, Inal, S., additional, Tekbudak, M., additional, Aygencel, G., additional, Onec, K., additional, Bali, M., additional, Sindel, S., additional, Soto, K., additional, Fidalgo, P., additional, Papoila, A. L., additional, Lentini, P., additional, Zanoli, L., additional, Granata, A., additional, Contestabile, A., additional, Basso, A., additional, Berlingo, G., additional, de Cal, M., additional, Pellanda, V., additional, Dell'Aquila, R., additional, Fortrie, G., additional, Stads, S., additional, van Bommel, J., additional, Zietse, R., additional, Betjes, M. G., additional, Berrada, A., additional, Arias, C., additional, Riera, M., additional, Orfila, M. A., additional, Rodriguez, E., additional, Barrios, C., additional, Peruzzi, L., additional, Chiale, F., additional, Camilla, R., additional, Martano, C., additional, Cresi, F., additional, Bertino, E., additional, Coppo, R., additional, Klimenko, A., additional, Villevalde, S., additional, Efremovtseva, M., additional, Kobalava, Z., additional, Pipili, C., additional, Ioannidou, S., additional, Kokkoris, S., additional, Poulaki, S., additional, Tripodaki, E.-S., additional, Parisi, M., additional, Papastylianou, A., additional, Nanas, S., additional, Wang, Y.-n., additional, Cheng, H., additional, Chen, Y.-p., additional, Wen, Z., additional, Li, X., additional, Shen, P., additional, Zou, Y., additional, Lu, Y., additional, Ma, X., additional, Chen, Y., additional, Ren, H., additional, Chen, X., additional, Chen, N., additional, Yue, T., additional, Elmamoun, S., additional, Wodeyar, H., additional, Goldsmith, C., additional, Abraham, A., additional, Wootton, A., additional, Ahmed, S., additional, Hill, C., additional, Curtis, S., additional, Miller, A., additional, Hine, T., additional, Stevens, K. K., additional, Patel, R. K., additional, Mark, P. B., additional, Delles, C., additional, Jardine, A. G., additional, Wilflingseder, J., additional, Heinzel, A., additional, Mayer, P., additional, Perco, P., additional, Kainz, A., additional, Mayer, B., additional, Oberbauer, R., additional, Huang, T.-M., additional, Wu, V.-C., additional, Park, D. J., additional, Bae, E. J., additional, Kang, Y.-J., additional, Cho, H. S., additional, Chang, S.-h., additional, Stramana, R., additional, Cognolato, D., additional, Baiocchi, M., additional, Chiella, B. M., additional, Pilla, C., additional, Balbinotto, A., additional, Antunes, V. H., additional, Heglert, A., additional, Collares, F. M., additional, Thome, F. S., additional, Gjyzari, A., additional, Thereska, N., additional, Xhango, O., additional, Xue, J., additional, Chen, M. C., additional, Wang, L., additional, Chen, Y. J., additional, Sun, X. Z., additional, An, W. S., additional, Kim, E. S., additional, Son, Y. K., additional, Kim, S. E., additional, Kim, K. H., additional, Oh, Y. J., additional, Tsai, H.-B., additional, Ko, W.-J., additional, Chao, C.-T., additional, Aarnoudse, A.-J. L., additional, Peride, I., additional, Radulescu, D., additional, Niculae, A., additional, Ciocalteu, A., additional, Checherita, A.-I., additional, Kao, C.-C., additional, Wang, C.-Y., additional, Lai, C.-F., additional, Chen, H.-H., additional, Wu, K.-D., additional, Klaus, F., additional, Goldani, J. C., additional, Cantisani, G., additional, Zanotelli, M. L., additional, Carvalho, L., additional, Klaus, D., additional, Garcia, V. D., additional, Keitel, E., additional, Hussaini, S. M., additional, Rao, P. N., additional, Kul, A., additional, Ye, N., additional, Zhang, Y., additional, Baines, R., additional, Westacott, R., additional, Trew, J., additional, Kirtley, J., additional, Selby, N., additional, Carr, S., additional, Xu, G., additional, Steffgen, J., additional, Blaschke, S., additional, Brun-Schulte-Wissing, N., additional, Pagel, P., additional, Huber, F., additional, Mapes, J., additional, Jaehnige, A., additional, Pestel, S., additional, Deray, G., additional, Rouviere, O., additional, Bacigalupo, L., additional, Maes, B., additional, Hannedouche, T., additional, Vrtovsnik, F., additional, Rigothier, C., additional, Billiouw, J.-M., additional, Campioni, P., additional, Marti-Bonmati, L., additional, Gao, Y.-m., additional, Li, D., additional, Woo, S., additional, Lee, J., additional, Noh, H., additional, Kwon, S. H., additional, Han, D. C., additional, Hetherington, L., additional, Valluri, A., additional, McQuarrie, E., additional, Fleming, S., additional, Geddes, C., additional, Bell, S., additional, MacKinnon, B., additional, Patton, A., additional, Sneddon, J., additional, Donnan, P., additional, Vadiveloo, T., additional, Marwick, C., additional, Bennie, M., additional, Davey, P., additional, Yasuda, H., additional, Tsuji, N., additional, Tsuji, T., additional, Iwakura, T., additional, Ohashi, N., additional, Kato, A., additional, Fujigaki, Y., additional, Sasaki, S., additional, Kawarazaki, H., additional, Shibagaki, Y., additional, Kimura, K., additional, Lingaraju, U., additional, Rajanna, S., additional, Radhakrishnan, H., additional, Parekh, A., additional, Sreedhar, C. G., additional, Sarvi, R., additional, Rainone, F., additional, Merlino, L., additional, Ritchie, J. P., additional, Kalra, P. A., additional, Jacinto, C. N., additional, Abreu, K. L. S., additional, Neves, M., additional, Baptista, J. P., additional, Rodrigues, L., additional, Pinho, J., additional, Teixeira, L., additional, Pimentel, J., additional, Gonzalez Sanchidrian, S., additional, Rangel Hidalgo, G., additional, Cebrian Andrada, C., additional, Deira Lorenzo, J., additional, Marin Alvarez, J., additional, Garcia-Bernalt Funes, V., additional, Gallego Dominguez, S., additional, Labrador Gomez, P., additional, Castellano Cervino, I., additional, Novillo Santana, R., additional, Gomez-Martino Arroyo, J., additional, Kim, Y., additional, Choi, B. S., additional, Kim, Y. o., additional, Yoon, S. A., additional, Lin, M.-C., additional, Wang, W.-J., additional, Melo, M. J., additional, Lopes, J. A., additional, Raimundo, M., additional, Fragoso, A., additional, Antunes, F., additional, Martin-Moreno, P. L., additional, Varo, N., additional, Restituto, P., additional, Sayon-Orea, C., additional, Garcia-Fernandez, N., additional, Leite Filho, N. C. V., additional, Souza, L. E. O., additional, Cavalcante, R. M., additional, Morais, B. M., additional, Leite, T. T., additional, Silva, S. L., additional, Kubrusly, M., additional, Jung, Y. S., additional, Kim, Y. N., additional, Shin, H. S., additional, Rim, H., additional, Bentall, A., additional, Al-Baaj, F., additional, Williamson, S., additional, Cheshire, S., additional, Jelakovic, M., additional, Ivkovic, V., additional, Laganovic, M., additional, Karanovic, S., additional, Pecin, I., additional, Premuzic, V., additional, Vukovic Lela, I., additional, Vrdoljak, A., additional, Fucek, M., additional, Cvitkovic, A., additional, Juric, D., additional, Bozina, N., additional, Bitunjac, M., additional, Leko, N., additional, Abramovic Baric, M., additional, Matijevic, V., additional, Jelakovic, B., additional, Ullah, A., additional, Exarchou, K., additional, Archer, T., additional, Anijeet, H., additional, Brown, R., additional, Cheng, Y.-p., additional, Rocha, J. C. G., additional, Gushiken da Silva, T., additional, de Castro, P. F., additional, Kioroglo, P. S., additional, Branco Martins, J. P., additional, Tzanno-Martins, C., additional, Biesenbach, P., additional, Luf, F., additional, Fleischmann, E., additional, Grunberger, T., additional, Druml, W., additional, Gaipov, A., additional, Turkmen, K., additional, Toker, A., additional, Solak, Y., additional, Cicekler, H., additional, Ucar, R., additional, Kilicaslan, A., additional, Gormus, N., additional, Tonbul, H. Z., additional, Yeksan, M., additional, Turk, S., additional, Monteburini, T., additional, Cenerelli, S., additional, Santarelli, S., additional, Boggi, R., additional, Tazza, L., additional, Bossola, M., additional, Ferraresi, M., additional, Merlo, I., additional, Giovinazzo, G., additional, Quercia, A. D., additional, Gai, M., additional, Leonardi, G., additional, Anania, P., additional, Guarena, C., additional, Cantaluppi, V., additional, Pacitti, A., additional, Biancone, L., additional, Hissa, P. N. G., additional, Daher, E. D. F., additional, Liborio, A. B., additional, Thereza, B. M. F., additional, Mendes, C. C. P., additional, and Sousa, A. R. O., additional

Published
2013
Full Text
View/download PDF

13. AKI - Clinical

Author

Gok Oguz, E., primary, Olmaz, R., additional, Turgutalp, K., additional, Muslu, N., additional, Sungur, M. A., additional, Kiykim, A., additional, Van Biesen, W., additional, Vanmassenhove, J., additional, Glorieux, G., additional, Vanholder, R., additional, Chew, S., additional, Forster, K., additional, Kaufeld, T., additional, Kielstein, J., additional, Schilling, T., additional, Haverich, A., additional, Haller, H., additional, Schmidt, B., additional, Hu, P., additional, Liang, X., additional, Chen, Y., additional, LI, R., additional, Jiang, F., additional, LI, Z., additional, Shi, W., additional, Lim, C. C. W., additional, Chia, C. M. L., additional, Tan, A. K., additional, Tan, C. S., additional, Ng, R., additional, Subramani, S., additional, Perez de Jose, A., additional, Bernis Carro, C., additional, Madero Jarabo, R., additional, Bustamante, J., additional, Sanchez Tomero, J. A., additional, Chung, W., additional, Ro, H., additional, Chang, J. H., additional, Lee, H. H., additional, Jung, J. Y., additional, Fazzari, L., additional, Giuliani, A., additional, Scrivano, J., additional, Pettorini, L., additional, Benedetto, U., additional, Luciani, R., additional, Roscitano, A., additional, Napoletano, A., additional, Coclite, D., additional, Cordova, E., additional, Punzo, G., additional, Sinatra, R., additional, Mene, P., additional, Pirozzi, N., additional, Shavit, L., additional, Manilov, R., additional, Algur, N., additional, Wiener-Well, Y., additional, Slotki, I., additional, Pipili, C., additional, Vrettou, C. S., additional, Avrami, K., additional, Economidou, F., additional, Glynos, K., additional, Ioannidou, S., additional, Markaki, V., additional, Douka, E., additional, Nanas, S., additional, De Pascalis, A., additional, Cofano, P., additional, Proia, S., additional, Valletta, A., additional, Vitale, O., additional, Russo, F., additional, Buongiorno, E., additional, Filiopoulos, V., additional, Biblaki, D., additional, Lazarou, D., additional, Chrysis, D., additional, Fatourou, M., additional, Lafoyianni, S., additional, Vlassopoulos, D., additional, Zakiyanov, O., additional, Kriha, V., additional, Vachek, J., additional, Svarcova, J., additional, Zima, T., additional, Tesar, V., additional, Kalousova, M., additional, Kaushik, M., additional, Ronco, C., additional, Cruz, D., additional, Zhang, L., additional, Zhang, W., additional, Chen, N., additional, Ejaz, A. A., additional, Kambhampati, G., additional, Ejaz, N., additional, Dass, B., additional, Lapsia, V., additional, Arif, A. A., additional, Asmar, A., additional, Shimada, M., additional, Alsabbagh, M., additional, Aiyer, R., additional, Johnson, R., additional, Chen, T.-H., additional, Chang, C.-H., additional, Chang, M.-Y., additional, Tian, Y.-C., additional, Hung, C.-C., additional, Fang, J.-T., additional, Yang, C.-W., additional, Chen, Y.-C., additional, Cantaluppi, V., additional, Quercia, A. D., additional, Figliolini, F., additional, Giacalone, S., additional, Pacitti, A., additional, Gai, M., additional, Guarena, C., additional, Leonardi, G., additional, Biancone, L., additional, Camussi, G., additional, Segoloni, G. P., additional, De Cal, M., additional, Lentini, P., additional, Clementi, A., additional, Virzi, G. M., additional, Scalzotto, E., additional, Lacquaniti, A., additional, Donato, V., additional, Fazio, M. R., additional, Lucisano, S., additional, Cernaro, V., additional, Lupica, R., additional, Buemi, M., additional, Helvaci, I., additional, Anik, E., additional, Wani, M., additional, Wani, D. I., additional, Bhat, D. M. A., additional, Banday, D. K., additional, Najar, D. M. S., additional, Reshi, D. A. R., additional, Palla, D. N. A., additional, Iglesias, P., additional, Olea, T., additional, Vega-Cabrera, C., additional, Heras, M., additional, Bajo, M. A., additional, Del Peso, G., additional, Arias, M. J., additional, Selgas, R., additional, Diez, J. J., additional, Daher, E., additional, Costa, P. L., additional, Pereira, E. N. S., additional, Santos, R. D. P., additional, Abreu, K. L., additional, Silva Junior, G., additional, Pereira, E. D. B., additional, Raimundo, M., additional, Crichton, S., additional, Syed, Y., additional, Martin, J., additional, Whiteley, C., additional, Bennett, D., additional, Ostermann, M., additional, Gjyzari, A., additional, Thereska, N., additional, Koroshi, A., additional, Barbullushi, M., additional, Kodra, S., additional, Idrizi, A., additional, Strakosha, A., additional, Petrela, E., additional, Lemmich Smith, J., additional, Klimenko, A., additional, Tuykhmenev, E., additional, Villevalde, S., additional, Kobalava, Z., additional, Avdoshina, S., additional, Tyukhmenev, E., additional, Efremovtseva, M., additional, Hayashi, H., additional, Suzuki, S., additional, Kataoka, K., additional, Kondoh, Y., additional, Taniguchi, H., additional, Sugiyama, D., additional, Nishimura, K., additional, Sato, W., additional, Maruyama, S., additional, Matsuo, S., additional, Yuzawa, Y., additional, Geraldine, D., additional, Muriel, F., additional, Alexandre, H., additional, Eric, R., additional, Fu, P., additional, Pozzato, M., additional, Ferrari, F., additional, Cecere, P., additional, Mesiano, P., additional, Vallero, A., additional, Livigni, S., additional, Quarello, F., additional, Hudier, L., additional, Decaux, O., additional, Haddj-Elmrabet, A., additional, Mandart, L., additional, Lino-Daniel, M., additional, Bridoux, F., additional, Renaudineau, E., additional, Sawadogo, T., additional, Le Pogamp, P., additional, Vigneau, C., additional, Famee, D., additional, Koo, H. M., additional, Oh, H. J., additional, Han, S. H., additional, Choi, K. H., additional, Kang, S.-W., additional, Mehdi, M., additional, Nicolas, M., additional, Mariat, C., additional, Shah, P., additional, Kute, V. B., additional, Vanikar, A., additional, Gumber, M., additional, Patel, H., additional, Trivedi, H., additional, Manetos, C., additional, Poulaki, S., additional, Tripodaki, E.-S., additional, Papastylianou, A., additional, Routsi, C., additional, Uchida, K., additional, Kensuke, U., additional, Yamagata, K., additional, Saitou, C., additional, Okada, M., additional, Chita, G., additional, Davies, M., additional, Veriawa, Y., additional, Naicker, S., additional, Mukhopadhyay, P., additional, Mukherjee, D., additional, Mishra, R., additional, Kar, M., additional, Zickler, D., additional, Wesselmann, H., additional, Schindler, R., additional, Gutierrez*, E., additional, Egido, J., additional, Rubio-Navarro, A., additional, Buendia, I., additional, Blanco-Colio, L. M., additional, Toldos, O., additional, Manzarbeitia, F., additional, De Lorenzo, A., additional, Sanchez, R., additional, Praga^, M., additional, Moreno^, J. A., additional, Kim, M. Y., additional, Kang, N. R., additional, Jang, H. R., additional, Lee, J. E., additional, Huh, W., additional, Kim, Y.-G., additional, Kim, D. J., additional, Hong, S.-C., additional, Kim, J.-S., additional, Oh, H. Y., additional, Okamoto, T., additional, Kamata, K., additional, Naito, S., additional, Tazaki, H., additional, Kan, S., additional, Anne-Kathrin, L.-G., additional, Matthias, K., additional, Speer, T., additional, Andreas, L., additional, Heinrich, G., additional, Thomas, V., additional, Poppleton, A., additional, Danilo, F., additional, Lai, C.-F., additional, Wu, V.-C., additional, Shiao, C.-C., additional, Huang, T.-M., additional, Wu, K.-D., additional, Bedford, M., additional, Farmer, C., additional, Irving, J., additional, Stevens, P., additional, Patera, F., additional, Mattozzi, F., additional, Battistoni, S., additional, Fagugli, R. M., additional, Park, M. Y., additional, Choi, S. J., additional, Kim, J. G., additional, Hwang, S. D., additional, Xie, H., additional, Chen, H., additional, Xu, S., additional, He, Q., additional, Liu, J., additional, Hu, W., additional, Liu, Z., additional, Dalboni, M., additional, Blaya, R., additional, Quinto, B. M., additional, Narciso, R., additional, Oliveira, M., additional, Monte, J., additional, Durao, M., additional, Cendoroglo, M., additional, Batista, M., additional, Hanemann, A. L., additional, Liborio, A., additional, Martins, A., additional, Pinheiro, M. C. C., additional, Meneses, G., additional, De Paula Pessoa, R., additional, Sousa, M., additional, Bezerra, F. S. M., additional, Albuquerque, P. L. M. M., additional, Lima, J. B., additional, Lima, C. B., additional, Veras, M. D. S. B., additional, Nemoto Matsui, T., additional, Totoli, C., additional, Cruz Andreoli, M. C., additional, Vilela Coelho, M. P., additional, Guimaraes de Souza, N. K., additional, Ammirati, A. L., additional, De Carvalho Barreto, F., additional, Ferraz Neto, B.-H., additional, Fortunato Cardoso Dos Santos, B., additional, Abraham, A., additional, Abraham, G., additional, Mathew, M., additional, Duarte, P. M. A., additional, Duarte, F. B., additional, Barros, E. M., additional, Castro, F. Q. S., additional, Palomba, H., additional, Castro, I., additional, Sousa, S. R., additional, Jesus, A. N., additional, Romano, T., additional, Burdmann, E., additional, Yu, L., additional, Kwon, S. H., additional, You, J. Y., additional, Hyun, Y. K., additional, Woo, S. A., additional, Jeon, J. S., additional, Noh, H. J., additional, Han, D. C., additional, Tozija, L., additional, Petronievic, Z., additional, Selim, G., additional, Nikolov, I., additional, Stojceva-Taneva, O., additional, Cakalaroski, K., additional, Lukasz, A., additional, Beneke, J., additional, Menne, J., additional, Schiffer, M., additional, Polanco, N., additional, Hernandez, E., additional, Gutierrez, E., additional, Gutierrez Millet, V., additional, Gonzalez Monte, E., additional, Morales, E., additional, Praga, M., additional, Francisco Javier, L., additional, Nuria, G.-F., additional, Jose Maria, M.-G., additional, Bes Rastrollo, M., additional, Angioi, A., additional, Conti, M., additional, Cao, R., additional, Atzeni, A., additional, Pili, G., additional, Matta, V., additional, Murgia, E., additional, Melis, P., additional, Binda, V., additional, Pani, A., additional, Thome*, F., additional, Leusin, F., additional, Barros, E., additional, Morsch, C., additional, Balbinotto, A., additional, Pilla, C., additional, Premru, V., additional, Buturovic-Ponikvar, J., additional, Ponikvar, R., additional, Marn-Pernat, A., additional, Knap, B., additional, Kovac, J., additional, Gubensek, J., additional, Kersnic, B., additional, Krnjak, L., additional, Prezelj, M., additional, Granatova, J., additional, Havrda, M., additional, Hruskova, Z., additional, Kratka, K., additional, Remes, O., additional, Mokrejsova, M., additional, Bolkova, M., additional, Lanska, V., additional, Rychlik, I., additional, Uniacke, M. D., additional, Lewis, R. J., additional, Harris, S., additional, Roderick, P., additional, Martin, N., additional, Ulrich, K., additional, Jan, B., additional, Jorn, B., additional, Reinhard, B., additional, Jan, K., additional, Hermann, H., additional, Meyer Tobias, F., additional, Leyla, R., additional, Schmidt Bernhard, M. W., additional, Harald, S., additional, Jurgen, S., additional, Tanja, K., additional, Mario, S., additional, Sang Hi, E., additional, Claus, M., additional, Frank, V., additional, Aleksej, S., additional, Sengul, S., additional, Robert, S., additional, Karin, W., additional, Feikah, G., additional, Menne Tobias, F., additional, Meyer Tobias, N., additional, Beutel, G., additional, Fleig, S., additional, Steinhoff, J., additional, Meyer, T., additional, Hafer, C., additional, Bramstedt, J., additional, Busch, V., additional, Vischedyk, M., additional, Kuhlmann, U., additional, Ries, W., additional, Mitzner, S., additional, Mees, S., additional, Stracke, S., additional, Nurnberger, J., additional, Gerke, P., additional, Wiesner, M., additional, Sucke, B., additional, Abu-Tair, M., additional, Kribben, A., additional, Klause, N., additional, Merkel, F., additional, Schnatter, S., additional, Dorresteijn, E., additional, Samuelsson, O., additional, Brunkhorst, R., additional, Stec-Hus Registry, G., additional, Reising, A., additional, Bange, F.-C., additional, Hiss, M., additional, Vetter, F., additional, Bode-Boger, S. M., additional, Martens-Lobenhoffer, J., additional, Schmidt, B. M. W., additional, Kielstein, J. T., additional, Shin, H. S., additional, Jung, Y. S., additional, and Rim, H., additional

Published
2012
Full Text
View/download PDF

14. Acute kidney injury - Human studies

Author

Locsey, L., primary, Seres, I., additional, Sztanek, F., additional, Harangi, M., additional, Padra, J., additional, Asztalos, L., additional, Paragh, G., additional, Hutchison, C. A., additional, Bevins, A., additional, Langham, R., additional, Mancini, E., additional, Wirta, O., additional, Cockwell, P., additional, Keir, R., additional, Vigano, M., additional, Stella, A., additional, Evans, N., additional, Chappell, M., additional, Fabbrini, P., additional, Onuigbo, M., additional, Onuigbo, N., additional, Kim, S., additional, Chang, J. H., additional, Jung, J. Y., additional, Lee, H. H., additional, Chung, W., additional, Zanoli, L., additional, Rastelli, S., additional, Marcantoni, C., additional, Tamburino, C., additional, Castellino, P., additional, Cho, A., additional, Choi, H., additional, Lee, J. E., additional, Jang, H. R., additional, Huh, W., additional, Kim, Y.-G., additional, Kim, D. J., additional, Oh, H. Y., additional, Garcia-Fernandez, N., additional, Martin-Moreno, P. L., additional, Varo, N., additional, Nunez-Cordoba, J. M., additional, Schlieper, G., additional, Kruger, T., additional, Kelm, M., additional, Floege, J., additional, Westenfeld, R., additional, Cho, A. J., additional, Doganay, S., additional, Oguz, A. K., additional, Ergun, I., additional, Bardachenko, N., additional, Kuryata, O., additional, Bardachenko, L., additional, Ravani, P., additional, Malberti, F., additional, Pirelli, S., additional, Scolari, F., additional, Barrett, B., additional, Presta, P., additional, Lucisano, G., additional, Rubino, A., additional, Serraino, F., additional, Amoruso, T., additional, Renzulli, A., additional, Fuiano, G., additional, Kielstein, J. T., additional, Tolk, S., additional, Heiden, A., additional, Kuhn, C., additional, Hoeper, M. M., additional, Lorenzen, J., additional, Broll, M., additional, Kaever, V., additional, Burhenne, H., additional, Hafer, C., additional, Haller, H., additional, Burkhardt, O., additional, Kielstein, J., additional, Zahalkova, J., additional, Petejova, N., additional, Strojil, J., additional, Urbanek, K., additional, Bertoli, S., additional, Musetti, C., additional, Cabiati, A., additional, Assanelli, E., additional, Lauri, G., additional, Marana, I., additional, De Metrio, M., additional, Rubino, M., additional, Campodonico, J., additional, Grazi, M., additional, Moltrasio, M., additional, Marenzi, G., additional, Unarokov, Z., additional, Mukhoedova, T., additional, Fidalgo, P., additional, Coelho, S., additional, Rodrigues, B., additional, Fernandes, A. P., additional, Papoila, A. L., additional, Liano, F., additional, Soto, K., additional, Vanmassenhove, J., additional, Vanholder, R., additional, Glorieux, G., additional, Van Biesen, W., additional, Challiner, R., additional, Ritchie, J., additional, Hutchison, A., additional, Zaharie, S. I., additional, Maria, D. T., additional, Zaharie, M., additional, Vaduva, C., additional, Grauntanu, C., additional, Cana-Ruiu, D., additional, Mota, E., additional, Hayer, M., additional, Baharani, J., additional, Thomas, M., additional, Eldehni, T., additional, Selby, N., additional, McIntyre, C., additional, Fluck, R., additional, Kolhe, N., additional, Fagugli, R. M., additional, Patera, F., additional, Shah, P. R., additional, Kaswan, K. K., additional, Kute, V. B., additional, Vanikar, A. V., additional, Gumber, M. R., additional, Patel, H. V., additional, Munjappa, B. C., additional, Enginner, D. P., additional, Sainaresh, V. V., additional, Trivedi, H. L., additional, Teixeira, C., additional, Nogueira, E., additional, Lopes, J. A., additional, Almeida, E., additional, Pais de Lacerda, A., additional, Gomes da Costa, A., additional, Franca, C., additional, Mariano, F., additional, Morselli, M., additional, Bergamo, D., additional, Hollo', Z., additional, Scella, S., additional, Maio, M., additional, Tetta, C., additional, Dellavalle, A., additional, Stella, M., additional, Triolo, G., additional, Cantaluppi, V., additional, Quercia, A. D., additional, Bertinetto, P., additional, Giacalone, S., additional, Tamagnone, M., additional, Basso, E., additional, Karvela, E., additional, Gai, M., additional, Leonardi, G., additional, Anania, P., additional, Guarena, C., additional, Fenocchio, C. M., additional, Pacitti, A., additional, Segoloni, G. P., additional, Kim, Y. O., additional, Kim, H. G., additional, Kim, B. S., additional, Song, H. C. S., additional, Min, J.-K., additional, Kim, S. Y., additional, Park, W. D., additional, Dalboni, M., additional, Narciso, R., additional, Quinto, M., additional, Grabulosa, C., additional, Cruz, E., additional, Monte, J., additional, Durao, M., additional, Cendoroglo, M., additional, Santos, O., additional, Batista, M., additional, Bellasi, A., additional, Giannone, S., additional, Mordenti, A., additional, Zanoni, A., additional, Santoro, A., additional, Lee, J. H., additional, Ha, S. H., additional, Kim, J. H., additional, Lee, G. J., additional, Jung, Y. C., additional, Malindretos, P., additional, Koutroumbas, G., additional, Patrinou, A., additional, Zagkotsis, G., additional, Makri, P., additional, Togousidis, I., additional, Syrganis, C., additional, Li Cavoli, G., additional, Tortorici, C., additional, Bono, L., additional, Ferrantelli, A., additional, Giammarresi, C., additional, Zagarrigo, C., additional, Rotolo, U., additional, Kim, H., additional, Jun, K., additional, Choi, W., additional, Krzesinski, J.-M., additional, Parotte, M.-C., additional, Vandevelde, C., additional, Keenan, J., additional, Dieterle, F., additional, Sultana, S., additional, Pinches, M., additional, Ciorciaro, C., additional, Schindler, R., additional, Schmitz, V., additional, Gautier, J.-C., additional, Benain, X., additional, Matchem, J., additional, Murray, P., additional, Adler, S., additional, Haase, M., additional, Haase-Fielitz, A., additional, Devarajan, P., additional, Bellomo, R., additional, Cruz, D. N., additional, Wagener, G., additional, Krawczeski, C. D., additional, Koyner, J. L., additional, Murray, P. T., additional, Zappitelli, M., additional, Goldstein, S., additional, Makris, K., additional, Ronco, C., additional, Martensson, J., additional, Martling, C.-R., additional, Venge, P., additional, Siew, E., additional, Ware, L. B., additional, Ikizler, A., additional, Mertens, P. R., additional, Lacquaniti, A., additional, Buemi, A., additional, Donato, V., additional, Lucisano, S., additional, Buemi, M., additional, Panagoutsos, S., additional, Kriki, P., additional, Mourvati, E., additional, Tziakas, D., additional, Chalikias, G., additional, Stakos, D., additional, Apostolakis, S., additional, Tsigalou, C., additional, Gioka, T., additional, Konstantinides, S., additional, Vargemezis, V., additional, Torregrosa, I., additional, Montoliu, C., additional, Urios, A., additional, Aguado, C., additional, Puchades, M. J., additional, Solis, M. A., additional, Juan, I., additional, Sanjuan, R., additional, Blasco, M., additional, Pineda, J., additional, Carratala, A., additional, Ramos, C., additional, Miguel, A., additional, Niculae, A., additional, Checherita, I. A., additional, Sandulovici, R., additional, David, C., additional, Ciocalteu, A., additional, Espinoza, M., additional, Hidalgo, J., additional, Lorca, E., additional, Santibanez, A., additional, Arancibia, F., additional, Gonzalez, F., additional, Park, M. Y., additional, Kim, E. J., additional, Choi, S. J., additional, Kim, J. K., additional, Hwang, S. D., additional, Lee, K.-h., additional, Seok, S.-J., additional, Yang, J.-O., additional, Lee, E.-Y., additional, Hong, S.-y., additional, Gil, H.-w., additional, Astapenko, E., additional, Shutov, A., additional, Savinova, G., additional, Rechnik, V., additional, Melo, M. J., additional, Raimundo, M., additional, Viegas, A., additional, Camara, I., additional, Antunes, F., additional, Kim, M.-J., additional, Kwon, S. H., additional, Lee, S. W., additional, Song, J. H., additional, and Lee, J. W., additional

Published
2011
Full Text
View/download PDF

22. CAPD in a large population: a 7-year experience

Author

Quarello, F., Bonello, F., Boero, R., Maffei, S., Beltrame, G., Belardi, P., Scalzo, B., Guarena, C., Piccoli, Giorgina Barbara, and Piccoli, Giuseppe

Subjects
Adult, Patient Dropouts, Acetates, Middle Aged, Peritonitis, Survival Analysis, Survival Rate, Bicarbonates, Peritoneal Dialysis, Continuous Ambulatory, Renal Dialysis, Dialysis Solutions, Humans, Kidney Failure, Chronic, Hemofiltration, Aged
Abstract

In this report we evaluate the results obtained with CAPD in uremic patients in Piedmont, a Northern Italian region (4.4 million inhabitants) during the last 7 years. Data are gathered from the computerized records of the regional dialysis and transplantation registry, which collects information on 3,567 pts, 2,243 of which entered since Jan. 1981 and 1,808 alive at Dec. 1987. Among these, 193 (11%) were on CAPD, a figure almost constant in the last 7 years. However CAPD diffusion is not uniform among the 20 centers of the region, ranging from 0 to 49.5% of the patients on dialysis. CAPD is particularly employed in the elderly (47.5% of the patients being older than 60 years and 19.5% over 70). This treatment was the first choice in 16% of the patients admitted to dialysis between 1981-87; this figure reaches 33% for the diabetics. High drop out rates still represent a major problem, in a 6 year follow up 66% of the patients being transferred to another dialysis treatment. Peritonitis is the main cause of drop out (22%), while loss of peritoneal membrane efficiency accounts for 7%, patient's choice 14%, catheter complications 14%, inability to cope 8%, clinical problems 20% and other reasons 15%. Drop out rate is not influenced by the presence of high risk condition or age. Survival curves show no significant difference for CAPD in comparison to hemodialysis in all the age groups considered. This epidemiological survey, based on a global 522 pts experience extended over a 7 year period, indicates that CAPD is a competitive mode of treatment in chronic uremia.

Published
1989

30. Imaging data suggesting acute pyelonephritis in the kidney graft: report of five cases with atypical clinical presentation

Author

Piccoli, Giorgina B., Picciotto, G., Rossetti, M., Burdese, M., Consiglio, V., Magnano, A., Soragna, G., Sargiotto, G., Maas, J., Guarena, C., Veglio, V., and Messina, M.

Subjects
*KIDNEY diseases, *NUCLEAR magnetic resonance, *URINALYSIS, *URINARY organs
Abstract

Abstract: Acute pyelonephritis is a common complication of kidney transplantation, occurring in up to 1% of grafts. Diagnosis is mainly clinical and atypical presentations have seldom been reported. The diagnostic role of imaging techniques has not been defined. Five cases of acute graft pyelonephritis are reported (three kidney, two pancreas–kidney grafts). The patients (median age 48 years) comprised three females and two males. Median post-transplant follow-up was 3 months, with three patients having predisposing factors for diabetes and one for an enteric bladder. None of the patients presented the ‘classic’ diagnostic tetrad (i.e. fever, positive urine cultures, low urinary tract symptoms and serum creatinine increase); although, at diagnosis, two of five patients presented with fever, one had increased creatinine levels and one had positive urine cultures. Of note, three patients had leucocyte casts at urinary sediment analysis, thus raising clinical suspicion. Renal ultrasounds were negative in all patients. Renal 99mTc-MAG3 (mercaptoacetyltriglycine) scintigraphy, which was used for the definition of kidney function impairment (one patient) or because of the presence of urinary casts (three patients), or after the biopsy diagnosis to locate the parenchymal lesions (one patient), was positive in all patients. The presence and pyelonephritic origin of the parenchymal lesions was confirmed by nuclear magnetic resonance or computed tomography scans. Acute graft pyelonephritis may develop in the absence of a full-blown clinical picture. Smouldering symptoms may occur in the presence of large perfusion deficits. 99mTc-MAG3 scintigraphy could be an important diagnostic tool in such cases. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

31. Implanted blood vessel external support device (VasQ™) for creation of hemodialysis arteriovenous fistula: A single-center experience.

Author

Leonardi G, Campagna M, Pellicanò V, Guarena C, Bergamo D, Lavacca A, Fop F, and Biancone L

Subjects
Aged, Aged, 80 and over, Female, Humans, Male, Prospective Studies, Renal Dialysis, Retrospective Studies, Time Factors, Treatment Outcome, Vascular Patency, Arteriovenous Fistula, Arteriovenous Shunt, Surgical adverse effects
Abstract

Introduction: the external support device VasQ is intended to promote arteriovenous fistula (AVF) maturation by maintaining the optimal anastomotic angle in order to minimize blood flow disturbances around the anastomotic area. The aim of the study is to assess efficacy and safety of the VasQ device both in brachiocephalic and radiocephalic fistulae., Methods: a single institution prospective study was conducted with implantation of the VasQ device during AVF creation. Clinical and Doppler ultrasounds evaluations were performed at day-1, 1, 6, and 12 months for assessment of device-related adverse events, AVF maturation and patency. Moreover, volume flow rate and diameter of outflow vein were measured. A total of 16 patients were enrolled. Ten brachiocephalic and 6 radiocephalic AVFs were created with VasQ. Preoperatively cephalic vein diameter was 3.6 ± 0.9 mm., Results: our population included 13 male and 3 females patients, 9 end stage kidney disease in conservative therapy, 4 dialysis treated patients, and 3 transplanted patients; mean age was 74.0 ± 8.1 years; no severe device-related adverse events were observed. Primary patency at 1, 6, and 12 months was 100%, 87.5%, and 67.7%, respectively, while secondary patency was 100%, 100%, and 78.3%, respectively. Comparing brachiocephalic to radiocephalic AVFs no significant differences in patency rates were seen. Overall maturation rate was 94% (15/16). Mean vein diameter measured with Doppler ultrasound at postoperative day-1 and at 1, 6, and 12 months was 5.0 ± 1.0, 5.9 ± 0.9, 7.2 ± 1.6, and 7.9 ± 1.4 mm, respectively, with a mean flow rate at the brachial artery of 841 ± 176, 1052 ± 224, 1261 ± 490, and 1348 ± 477 ml/min, respectively., Conclusions: in our limited experience VasQ was safe, with high maturation and patency rates. Positive results suggest a potential benefit for VasQ in AVF.

Published
2021
Full Text
View/download PDF

32. Hemodialysis arteriovenous fistula ligation after renal transplantation: Impact on graft resistive index.

Author

Magnetti M, Leonardi G, Guarena C, Dolla C, Tarragoni R, Abbasciano I, Fop F, Tallia C, Giordano F, Verri A, and Biancone L

Subjects
Adult, Aged, Blood Flow Velocity, Female, Humans, Ligation, Male, Middle Aged, Prospective Studies, Regional Blood Flow, Time Factors, Treatment Outcome, Vascular Resistance, Arteriovenous Shunt, Surgical adverse effects, Arteriovenous Shunt, Surgical mortality, Graft Survival, Hemodynamics, Kidney Transplantation adverse effects, Kidney Transplantation mortality, Renal Circulation, Renal Dialysis
Abstract

Background: Kidney allograft resistive index (RI) is prognostic for graft and recipient survivals. Recipient hemodynamics could influence RI. In particular, dialysis arteriovenous fistula (AVF) has been involved in heart function changes, reversible after AVF ligation. Knowledge about AVF and RI is lacking. In this study, we prospectively evaluated RI changes after AVF ligation in kidney transplanted patients., Methods: We enrolled 22 stable transplanted patients. Mean RI was measured before AVF ligation (T0), 18 to 24 h (T1) and 6 months (T6) after surgery; mean blood pressure (mBP), heart rate (HR), serum creatinine (sCr), estimated glomerular filtration rate (eGFR), 24 h proteinuria (24 h-P), immunosuppressive drug blood levels (IS) and antihypertensive drugs were also recorded., Results: AVF ligation was performed 3.1 years (IQR: 2.1-3.8) after transplantation. Median AVF flow (Qa) was 1868 mL/min (IQR: 1538-2712) and 8 AVF were classified as high flow (Qa ≥ 2 L/min). At baseline, median sCr was 1.32 mg/dL (IQR: 1.04-1.76) and median eGFR was 57.1 mL/min. Median RI was 0.71 at T0, 0.69 at T1, 0.66 at T6. RI reduction at T1 and T6 was statistically significant (p < 0.05 and p < 0.001 respectively); in particular, 90.4% of patients had persistently improved values at T6. Furthermore, mBP increased while HR decreased. These changes were independent from sCr, 24 h-P, IS, antihypertensive drugs number, Qa and AVF type., Conclusions: AVF ligation improves kidney allograft RI; it may reflect better kidney perfusion.

Published
2021
Full Text
View/download PDF

33. Citrate anion improves chronic dialysis efficacy, reduces systemic inflammation and prevents Chemerin-mediated microvascular injury.

Author

Dellepiane S, Medica D, Guarena C, Musso T, Quercia AD, Leonardi G, Marengo M, Migliori M, Panichi V, Biancone L, Pizzarelli F, Camussi G, and Cantaluppi V

Subjects
C-Reactive Protein analysis, Chemokines blood, Endothelium, Vascular injuries, Endothelium, Vascular metabolism, Female, Fibrinogen analysis, Hemodialysis Solutions, Humans, Inflammation etiology, Interleukin-6 blood, Male, Microvessels metabolism, Middle Aged, Muscle, Smooth, Vascular injuries, Muscle, Smooth, Vascular metabolism, Renal Dialysis methods, Treatment Outcome, Chemokines metabolism, Citric Acid therapeutic use, Inflammation prevention & control, Microvessels injuries, Renal Dialysis adverse effects
Abstract

Systemic inflammation and uremic toxins (UT) determine the increased cardiovascular mortality observed in chronic hemodialysis (HD) patients. Among UT, the adipokine Chemerin induces vascular dysfunction by targeting both endothelial and vascular smooth muscular cells (EC and VSMC). As Citrate anion modulates oxidative metabolism, systemic inflammation and vascular function, we evaluated whether citrate-buffered dialysis improves HD efficiency, inflammatory parameters and chemerin-mediated microvascular injury. 45 patients were treated in sequence with acetate, citrate and, again, acetate-buffered dialysis solution (3 months per interval). At study admission and after each treatment switch, we evaluated dialysis efficacy and circulating levels of chemerin and different inflammatory biomarkers. In vitro, we stimulated EC and VSMC with patients' plasma and we investigated the role of chemerin as UT. Citrate dialysis increased HD efficacy and reduced plasma levels of CRP, fibrinogen, IL6 and chemerin. In vitro, patients' plasma induced EC and VSMC dysfunction. These effects were reduced by citrate-buffered solutions and paralleled by the decrease of chemerin levels. Consistently, chemerin receptor knockdown reduced EC and VSMC dysfunction. In conclusion, Switching from acetate to citrate improved dialysis efficacy and inflammatory parameters; in vitro, chemerin-induced EC and VSMC injury were decreased by using citrate as dialysis buffer.

Published
2019
Full Text
View/download PDF

34. [Efficacy of SUPRA HFR in the treatment of acute renal damage during multiple myeloma].

Author

Daidola G, Guarena C, Brustia M, Leonardi G, Vigotti FN, Marciello A, Bianco S, Chiarinotti D, Saltarelli M, Besso L, and Biancone L

Subjects
Acute Kidney Injury etiology, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Female, Humans, Immunoglobulin Light Chains metabolism, Male, Middle Aged, Multiple Myeloma drug therapy, Myeloma Proteins metabolism, Plasmapheresis, Treatment Outcome, Acute Kidney Injury therapy, Hemodiafiltration methods, Multiple Myeloma complications
Abstract

Acute Kidney Injury (AKI) is a frequent complication of multiple myeloma (MM) with unfavorable prognostic significance. Light chains removal, combined with hematological therapy (CT) seems to offer significant benefits to renal function recovery (RFR). The SUPRA HFR, through the combination of high cut-off membrane without albumin loss and adsorbent cartridge, represents one of the "emerging" light chain removal methods. We report our multicentric retrospective experience with SUPRA HFR in 7 MM patients. At the end of the treatment with SUPRA HFR a significant reduction in serum free light chains compared to baseline was observed (min 24%; max 90%; median 74%). Despite a not always early start of the treatment, all patients recovered renal function with withdrawal from dialysis in 6/7 cases. Our preliminary experience of a combination of SUPRA HFR treatment with CT in 7 MM patients with AKI showed a significative renale functional recovery, with favourable cost/benefit ratio and a simple treatment schedule. These encouraging data suggest to further extend such treatment option, waiting for larger studies in this field., (Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.)

Published
2018

35. Metformin-Associated Lactic Acidosis Undergoing Renal Replacement Therapy in Intensive Care Units: A Five-Million Population-Based Study in the North-West of Italy.

Author

Mariano F, Pozzato M, Inguaggiato P, Guarena C, Turello E, Manes M, David P, Berutti S, Consiglio V, Amore A, Campo A, Marino A, Berto M, Carpani P, Calabrese G, Gherzi M, Stramignoni E, Martina G, Serra A, Comune L, Roscini E, Marciello A, Todini V, Vio P, Filiberti O, Boero R, and Cantaluppi V

Subjects
Aged, Female, Humans, Italy, Male, Metformin administration & dosage, Retrospective Studies, Acidosis, Lactic chemically induced, Acidosis, Lactic epidemiology, Acidosis, Lactic therapy, Critical Care, Intensive Care Units, Metformin adverse effects, Renal Replacement Therapy
Abstract

Background: Metformin-associated lactic acidosis (MALA) is a severe complication of drug administration with significant morbidity and mortality. So far no study in large population areas have examined the incidence, clinical profile and outcome of acute kidney injury (AKI)-MALA patients admitted in intensive care units (ICUs) and treated by renal replacement therapy (MALA-RRT)., Methods: Retrospective analysis over a 6-year period (2010-2015) in Piedmont and Aosta Valley regions (5,305,940 inhabitants, 141,174 diabetics treated with metformin) of all MALA-RRT cases., Results: One hundred and seventeen cases of AKI-MALA-RRT were observed (12.04/100,000 metformin treated diabetics, 1.45% of all RRT-ICU patients). Survival rate was 78.3%. The average duration of RRT was 4.0 days at mean dialysis effluent of 977 mL/kg/day. At admission most patients were dehydrated, and experienced shock and oliguria., Conclusion: Our data showed that MALA-RRT is a common complication, needing more prevention. Adopted policy of early, extended, continuous and high efficiency dialysis could contribute to an observed high survival rate. Video Journal Club "Cappuccino with Claudio Ronco" at http://www.karger.com/?doi=471917., (© 2017 S. Karger AG, Basel.)

Published
2017
Full Text
View/download PDF

36. ["Getting to zero infections" in hemodialysis].

Author

Leonardi G, Finotto G, Talaia M, Nappo A, Dolla C, Di Vico MC, Diena D, Linsalata A, Guarena C, Barbaro S, and Biancone L

Subjects
Humans, Anti-Infective Agents, Local therapeutic use, Bandages, Catheter-Related Infections prevention & control, Chlorhexidine therapeutic use, Education, Nursing, Renal Dialysis
Abstract

Introduction: We describe two measures adopted in hemodialysis outpatient population in order to reduce Central Venous Catheter (CVC) related infections. The first is a nurse staff training in the field project and the second deals with the employment of chlorhexidine-impregnated dressing devices. These actions were performed after high infection rates were observed through a dedicated register., Materials and Methods: In the limited assistance dialysis center, direct observation (12/2012-02/2013) quantified the gap between the observed and expected health care behaviour. Training needs were defined and a 40 hours nurse staff training in the field was performed on two occasions. In the hospital dialysis center, we introduced alcoholic 2% chlorhexidine solution and chlorhexidine-impregnated dressing devices to the exit site (CHG-Tegaderm and BioPatch). Infections (cumulatively bacteremia/sepsis/skin exit/subcutaneous tunnel) were monitored continuously., Results: Infection rates at the two locations were progressively reduced, reaching a value of zero at the limited assistance center. Nurse staff training in the field produced: two patient reports and three CVC management protocols, Italian language translation of the "The 5 moments of dialysis" WHO poster, alcoholic 2% chlorhexidine adoption to exit-site medication and improvement of environment cleaning/sanitation actions., Conclusions: Our experience shows that continuously monitoring infection rates represents the first step for timely corrective action. The continuous updating of health personnel, codified prevention measures and an ongoing commitment to raise awareness in a routine practice, allows us to obtain the goal of "getting to zero infections". The staff training produced equal or superior results compared to the isolated use of new chlorhexidine-impregnated dressing devices.

Published
2015

37. Mitochondrial neurogastrointestinal encephalomyopathy treated with peritoneal dialysis and bone marrow transplantation.

Author

Ariaudo C, Daidola G, Ferrero B, Guarena C, Burdese M, Segoloni GP, and Biancone L

Subjects
Fatal Outcome, Female, Humans, Intestinal Pseudo-Obstruction diagnosis, Mitochondrial Encephalomyopathies diagnosis, Muscular Dystrophy, Oculopharyngeal, Ophthalmoplegia congenital, Young Adult, Bone Marrow Transplantation, Intestinal Pseudo-Obstruction therapy, Mitochondrial Encephalomyopathies therapy, Peritoneal Dialysis
Abstract

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare disease caused by thymidine phosphorylase deficiency which leads to toxic accumulations of thymidine (dThd) and deoxyuridine (dUrd). It lacks an established treatment and the prognosis is traditionally poor. We report a case of a young female patient with normal renal function and MNGIE treated by peritoneal dialysis (PD) and allogeneic bone marrow transplantation (BMT). PD was effective in reducing dThd and dUrd plasma levels and in improving clinical symptoms. To our knowledge, this is the first report on the beneficial effects of PD regarding MNGIE neurological symptoms. PD, therefore, should be considered especially in medically compromised patients as a supportive treatment to improve clinical conditions before BMT.

Published
2015
Full Text
View/download PDF

38. Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis.

Author

Gai M, Merlo I, Dellepiane S, Cantaluppi V, Leonardi G, Fop F, Guarena C, Grassi G, and Biancone L

Subjects
Aged, Diabetes Complications, Diabetes Mellitus pathology, Diabetes Mellitus therapy, Extracellular Fluid chemistry, Female, Glycated Hemoglobin metabolism, Humans, Kidney Failure, Chronic complications, Kidney Failure, Chronic pathology, Kidney Failure, Chronic therapy, Male, Middle Aged, Monitoring, Physiologic, Diabetes Mellitus metabolism, Glucose metabolism, Glycemic Index, Kidney Failure, Chronic metabolism, Renal Dialysis
Abstract

Background/aims: Recent evidences suggest that hemodialysis (HD) induces glycemic variations in diabetic patients. Continuous glucose monitoring (CGM) devices measure interstitial glucose in a 'Holter-like' manner thereby improving the glycemic control assessment method., Methods: A CGM device (Medtronic iPRO) was used on 12 diabetic patients with chronic HD for 6 days to assess intra- and extra-dialytic interstitial glucose., Results: In all enrolled patients, HD was associated with a decrease of interstitial glucose values. Intradialytic glucose nadir was 79 mg/dl and it was reached at the third hour after the beginning of the session. At the end of HD, interstitial glucose increased in all patients and a glycemic peak (187 mg/dl) occurred after an average time of 2.5 h. No episodes of nocturnal hypoglycemia occurred., Conclusion: HD is associated with significant intradialytic reduction of glycemia and postdialytic hyperglycemia. CGM devices result in better monitoring of glycemic trends in diabetic patients on chronic HD and could improve insulin management., (© 2014 S. Karger AG, Basel.)

Published
2014
Full Text
View/download PDF

39. Sirolimus and ACE-inhibitors: a note of caution.

Author

Burdese M, Rossetti M, Guarena C, Consiglio V, Mezza E, Soragna G, Gai M, Segoloni GP, and Piccoli GB

Subjects
Angiotensin-Converting Enzyme Inhibitors adverse effects, Antihypertensive Agents adverse effects, Antihypertensive Agents therapeutic use, Drug Interactions, Female, Humans, Male, Middle Aged, Ramipril adverse effects, Ramipril therapeutic use, Sirolimus adverse effects, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Immunosuppressive Agents adverse effects, Kidney Transplantation immunology, Sirolimus therapeutic use
Published
2005
Full Text
View/download PDF

40. Tailored immunosuppression and steroid withdrawal in pancreas-kidney transplantation.

Author

Rossetti M, Piccoli GB, Burdese M, Guarena C, Giraudi R, Mezza E, Consiglio V, Soragna G, Messina M, and Segoloni GP

Abstract

Background: Recent improvements in simultaneous pancreas-kidney transplantation (SPK) and the striking decrease in acute rejection lead us to focus on the effects of long-term immunosuppression., Aim of This Study: Evaluation of a policy of steroid withdrawal and tailored immunosuppression in pancreas-kidney patients treated in a single center., Methods: review of the clinical charts in 9 SPK recipients (male/female = 5/4, median age 41 years, median follow-up 42 months), by the same operator, under supervision of the two usual caregivers. Therapeutic protocols. Induction phase: all patients received mycophenolate mophetil (starting dose: 2 grams), tacrolimus and steroids, 8 received Simulect, 1 received thymoglobulins. Maintenance therapy was slowly reduced, with the goal of steroid withdrawal., Results: The therapeutic adjustments were mainly determined by two almost opposing elements: 1. Rapid adjustments in the case of side-effects (gastrointestinal problems, infections and neoplasia); 2. Slow tapering off in the case of good organ function. On the other hand, a switch to cyclosporine A and to rapamycine was considered in the case of chronic organ malfunction. By these means, over a median of 42 months follow-up, steroid withdrawal was slowly obtained in 6/9 patients (at a median time of 25 months)., Conclusions: Within the limits of this small-scale study, a tailored immunosuppressive policy allows at least some "positively selected" patients to reach the "dream" of steroid withdrawal after SPK.

Published
2004
Full Text
View/download PDF

41. Continuum of therapy in progressive renal diseases (from predialysis to transplantation): analysis of a new organizational model.

Author

Piccoli G, Piccoli GB, Mezza E, Burdese M, Rosetti M, Guarena C, Messina M, Pacitti A, Thea A, Malfi B, Soragna G, Gai M, Mangiarotti G, Jeantet A, and Segoloni GP

Subjects
Adult, Aged, Aged, 80 and over, Ambulatory Care Facilities, Chronic Disease, Disease Progression, Female, Hemodialysis Units, Hospital, Hemodialysis, Home, Holistic Health, Hospitals, University, Humans, Italy, Kidney Diseases pathology, Male, Middle Aged, Nephrology education, Nephrology organization & administration, Patient Compliance, Continuity of Patient Care organization & administration, Kidney Diseases therapy, Kidney Transplantation, Models, Organizational, Physician-Patient Relations, Progressive Patient Care organization & administration, Renal Dialysis
Abstract

In the aging of Western populations, decreased mortality is counterbalanced by an increase in morbidity, particularly involving chronic diseases such as most renal diseases. The price of the successful care of chronic conditions, such as cardiovascular diseases or diabetes, is a continuous increase in new dialysis patients. However, the increased survival of patients on chronic renal replacement therapies poses new challenges to nephrologists and calls for new models of care. Since its split from internal medicine, nephrology has seen a progressive trend toward super specialization and the differentiation into at least 3 major branches (nephrology, dialysis, and transplantation), following a path common to several other fields of internal medicine. The success in the care of chronic patients is owed not only to a careful technical prescription, but also to the ability to teach self-care and attain compliance; this requires good medical practice and a sound patient-physician relationship. In this context, the usual models of care may fail to provide adequate coordination and, despite valuable single elements, could end up as an orchestra without a conductor. We propose an integrated model of care oriented to the type of patient (tested in our area especially for diabetic patients): the patient is followed-up by the same team from the first signs of renal disease to eventual dialysis or transplantation. This model offers an interesting alternative both for patients, who usually seek continuity of care, and for nephrologists who prefer a holistic and integrated patient-physician approach.

Published
2004
Full Text
View/download PDF

42. Patients on renal replacement therapy for 20 or more years: a clinical profile.

Author

Piccoli GB, Mezza E, Anania P, Iadarola AM, Vischi M, Torazza MC, Fop F, Guarena C, Martina G, Messina M, Jeantet A, Segoloni GP, and Piccoli G

Subjects
Adult, Bone Diseases epidemiology, Cardiovascular Diseases epidemiology, Comorbidity, Cross-Sectional Studies, Depression epidemiology, Female, Follow-Up Studies, Humans, Hypertension epidemiology, Italy, Kidney Failure, Chronic etiology, Liver Diseases epidemiology, Male, Middle Aged, Neoplasms epidemiology, Patient Selection, Prevalence, Time Factors, Vision Disorders epidemiology, Kidney Failure, Chronic therapy, Renal Replacement Therapy adverse effects
Abstract

Background: Long-term survivors are living evidence of the goals and limits of renal replacement therapy (RRT)., Methods: A cross-sectional study was performed on all cases (188 patients) with RRT follow-up >/=20 years in Piemonte, northern Italy (4 350 000 inhabitants, 22 dialysis centres). Study included revision of clinical charts and assessment of functional (Karnofsky scale, Ks) and nutritional status (subjective global assessment, SGA). According to treatment history, patients were sorted into three groups: group 1, 56 patients always on dialysis; group 2, 40 patients on dialysis with previous graft; group 3, 92 grafted patients., Results: Age differed between group 1 and groups 2 and 3 (59.5+/-11.5 vs 51.5+/-7.9 and 51.0+/-9.0 years; P=0.001). Prevalence of comorbidity was higher in groups 1 and 2 (94.6% and 95%) compared with group 3 (81.5%), reflecting selection during follow-up. Twenty-two cases (11.7%) had no comorbidity; these patients were younger (44.3+/-8.5 years) and 17 out of 22 had a functioning graft. The most common comorbidities were vasculopathy (73.4%), bone disease (72.9%) and cardiopathy (33.5%). Severe visual impairment was a common problem (18%), with a higher prevalence in patients with cardiovascular comorbidity (32%). Severe depression was found in 13.3% of cases. Despite comorbidity, functional scores (Ks) were good (higher in group 3 (88.1+/-15) than in groups 1 and 2 (67.9+/-21.9 and 75.5+/-18, respectively); P=0.000) and 64% of patients were well nourished. The combination of cardiovascular comorbidity, bone disease and visual impairment may reflect the premature ageing of RRT patients., Conclusion: Despite the high prevalence of comorbidity, long-term follow-up may promote good clinical conditions at least in some patients, highlighting the therapeutic potentials of dialysis in an era of reconsideration of open acceptance of RRT.

Published
2002
Full Text
View/download PDF

43. [Biopsy experience at the G. Bosco Hospital from 1996 to 1999].

Author

Quattrocchio G, Rollino C, Beltrame G, Massara C, Guarena C, Mazzucco G, Sandrone M, Boero R, and Quarello F

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Hospitals, Humans, Italy, Male, Middle Aged, Retrospective Studies, Biopsy, Needle, Kidney Diseases pathology
Abstract

Background: Aim of this study was a retrospective analysis of the renal biopsies performed in our Division., Methods: Since January 1, 1996 to September 30, 1999 289 biopsies were performed on native kidneys, 90 patients were older than 65., Results: The most frequent nephropathy was IgA glomerulonephritis (IgAGN) (28%), followed by membranous glomerulonephritis (MGN) (11%). In patients older than 65, the most frequent was MGN (20%), followed by IgAGN (12.2%). The total complications were 84 (29.1%) (hematomas >3 cm 1%; blood transfusion: 1.4%). Complications were not related to age, blood pressure, renal function, clinical presentation, number of shots. In 217 patients, the results obtained with two different modalities were compared: manual system (needle size=15 gauge) and automatic system (18 gauge). No statistically significant differences were found as regards the number of shots for single biopsy, number of glomeruli and major complications (1.6% vs 1.3%), while minor complications were more frequent in the second group., Conclusions: In conclusion, the number of renal biopsies performed in our Division has been increasing year after year. This trend can be partially explained by our wider indications to renal biopsy in elderly population (the data related to resident population showed the greatest prevalence of biopsies in patients 70 to 79 years old). Renal biopsy actually represents a safe examination even in elderly patients. From a technical point of view, on the basis of personal experience, 18 gauge acecut automatic needles seem to be preferred to other kind of devices.

Published
2001

44. Red blood cell Na(+)-K+ pump activity and arterial hypertension in autosomal dominant polycystic kidney disease.

Author

Boero R, Guarena C, Carbone D, and Piccoli G

Subjects
Adolescent, Adult, Blood Pressure, Female, Humans, Hypertension etiology, Male, Middle Aged, Polycystic Kidney, Autosomal Dominant complications, Sodium metabolism, Erythrocytes enzymology, Hypertension blood, Polycystic Kidney, Autosomal Dominant blood, Sodium-Potassium-Exchanging ATPase metabolism
Published
1996
Full Text
View/download PDF

45. [Abnormal erythrocyte sodium transport in patients with adult polycystic kidney and hypertension].

Author

Guarena C, Boero R, Quarello F, Berto I, Muraca R, Roux V, Iadarola G, and Piccoli G

Subjects
Adult, Age Factors, Biological Transport, Active, Female, Humans, Hypertension etiology, Ion Pumps, Male, Polycystic Kidney Diseases complications, Erythrocyte Membrane metabolism, Hypertension metabolism, Polycystic Kidney Diseases metabolism, Sodium metabolism
Abstract

The aim of this work was to evaluate the intracellular Na concentration, the passive Na permeability and the activity of Na, K pump, Na, K cotransport, Na, Li countertransport in the red cells of patients with autosomal dominant polycystic kidney disease (ADPKD) in relationship with their blood pressure status. Sixteen patients with ADPKD and normal renal function (6 males, 10 females, median age 31.5 years, range 20-42 years) and twenty healthy controls (10 males, 10 females, median age 30 years, range 23-47 years) were studied. Eight ADPKD were hypertensive. The rate constant of ouabain-sensitive Na efflux was lower in hypertensive than in normotensive ADPKD patients. The activity of Na,Li countertransport was significantly higher in hypertensive ADPKD patients than in both normotensive patients and control subjects. A significant inverse correlation was found between Na,Li countertransport activity and the rate constant of ouabain-sensitive Na efflux in fresh red cells (rho = 0.62; p = 0.016). Hypertension in patients with ADPKD and normal renal function is associated with abnormalities of red cell sodium transport: an increase of Na,Li countertransport, possibly primitive, and a reduction of Na,K pump in fresh cells, possibly secondary to a circulating inhibitor.

Published
1993

46. [Erythrocyte sodium-lithium countertransport in diabetic children: 12 months development and relationship with familial hypertension].

Author

Guarena C, Boero R, Quarello F, Cerruti F, Rolando B, Sacchetti C, Rosati C, Iadarola G, and Piccoli G

Subjects
Child, Diabetes Mellitus, Type 1 genetics, Diabetic Nephropathies blood, Female, Follow-Up Studies, Humans, Hypertension blood, Male, Risk, Antiporters, Carrier Proteins blood, Diabetes Mellitus, Type 1 blood, Erythrocytes metabolism, Hypertension genetics
Abstract

It has been suggested that an increased erythrocyte Na-Li countertransport (Na-Li CNT) rate in patients with IDDM is associated to the risk of developing diabetic nephropathy. Little is known, however, about the possible influence of metabolic control on Na-Li activity. Aims of the study were to evaluate Na-Li CNT at the onset of IDDM and during the remission phase and its relationship with some clinical and metabolic parameters. Twelve insulin-dependent diabetic children (6 males, 6 females; mean age 10 +/- 0.6 years) were studied at the onset and 1, 4, 12 months after the diagnosis; 6 of them had a family history of hypertension. Twelve healthy children (6 males, 6 females; mean age 12 +/- 0.3 years) served as controls. As compared to control subjects (212 +/- 24 mumol/l RBC/h), red cell Na-Li countertransport activity of diabetic children was significantly higher at the onset (354 +/- 31 mumol/l RBC/h) of IDDM and at the first month (348 +/- 36 mumol/l RBC/h). Red cell Na-Li countertransport activity returned toward normal range at the fourth (239 +/- 33 mumol/l RBC/h) and twelfth month (162 +/- 34 mumol/l RBC/h). No correlation was found between the values of red cell Na-Li countertransport activity and those of clinical and biochemical parameters at any time. Patients with hypertensive relatives showed at baseline evaluation a significantly higher red cell Na-Li countertransport activity than those without (436 +/- 28 vs 273 +/- 34 mumol/l RBC/h; p < 0.002). This difference, although not statistically significant, was still evident at the late follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1992

47. [Changes in cellular ion transport and arterial pressure in renal transplant recipients undergoing cyclosporin treatment].

Author

Borca M, Guarena C, Boero R, Basolo B, Maffei S, Forneris G, Iadarola GM, Stramignoni E, and Quarello F

Subjects
Adult, Azathioprine therapeutic use, Cyclosporine blood, Cyclosporine pharmacology, Erythrocytes enzymology, Female, Humans, Hypertension blood, Male, Prednisone therapeutic use, Sodium-Potassium-Exchanging ATPase blood, Cyclosporine adverse effects, Hypertension chemically induced, Kidney Transplantation, Postoperative Complications chemically induced, Sodium-Potassium-Exchanging ATPase drug effects
Abstract

Arterial hypertension is a common side effect of cyclosporine A (CyA). Aim of the study was to evaluate the activity of erythrocyte (RBC) Na transport in two groups of patients with a well functioning renal graft (Crs less than 1.7 mg/dl) treated by prednisone+azathioprine (10 pts), or prednisone+CyA (21 pts), in relationship with blood pressure status. Twenty-one age matched healthy subjects were studied as a control group. Na,K pump and Na,K cotransport were significantly lower in CyA than in AZA patients (2,184 +/- 106 vs 3,089 +/- 162 and 58 +/- 8 vs 187 +/- 28 mumol/l RBC/h: p less than 0.01), without differences between normotensive and hypertensive patients. Na,K pump efflux in normal subjects was 2334 +/- 66 mumol/l RBC/h (p less than 0.01 vs AZA), NA,K cotransport was 205 +/- 18 mumol/l RBC/h (p less than 0.01 vs CyA). Significant correlations were found between RBC Na,K pump activity and trough plasma CyA levels (p less than 0.02) and between systolic pressure and plasma creatinine in CyA patients (p less than 0.01). Trough plasma CyA levels were higher in hypertensive than in normotensive CyA patients (64 +/- 5 vs 46 +/- 4 ng/ml; p less than 0.01).

Published
1992

48. [Effects of saline infusion on the activity of erythrocyte sodium-potassium pump in normal subjects and in patients with essential hypertension].

Author

Forneris G, Boero R, Guarena C, Maffei S, Stramignoni E, Iadarola GM, Borca M, and Quarello F

Subjects
Adult, Erythrocytes drug effects, Female, Humans, Hypertension blood, Infusions, Intravenous, Male, Sodium urine, Sodium Chloride administration & dosage, Erythrocytes metabolism, Hypertension metabolism, Sodium Chloride pharmacology, Sodium-Potassium-Exchanging ATPase drug effects
Abstract

The effects of a 2 litre isotonic saline infusion on erythrocyte Na,K pump activity and urinary sodium excretion (UNaV) were evaluated in 20 patients with essential hypertension and 15 normotensive subjects. The effect of preincubation of normal erythrocytes in plasma from hypertensive patients on erythrocyte Na,K pump was also studied. Before saline infusion no significant differences were found between normotensive and hypertensive subjects in the mean values of intracellular sodium and potassium concentration, ouabain-sensitive Na efflux in erythrocytes and urinary sodium excretion. Erythrocyte Na,K pump activity decreased significantly (p less than 0.01) after saline infusion in both groups of subjects. The reduction was significantly lower in hypertensives than in normotensive. delta UNaV was significantly higher in hypertensive patients than in normotensive subjects (25 +/- 4 vs 14 +/- 2 mmol/h; p = 0.04). Only in normal subjects a significant correlation was found between the difference in Na,K pump activity pre and post saline infusion and delta UNaV (r = 0.52; p less than 0.05). Plasma from hypertensive patients obtained before saline infusion significantly (p less than 0.01) inhibited Na,K pump of erythrocytes from normal subjects; plasma taken after saline infusion produced a marked increase of this inhibition, significantly (p less than 0.01) higher than serum taken before the infusion.

Published
1992

49. Increased sodium-lithium countertransport activity in red cells of IgA nephropathy patients.

Author

Boero R, Degli Esposti E, Fabbri A, Guarena C, Forneris G, Quarello F, Fusaroli M, and Piccoli G

Subjects
Adult, Biological Transport, Active, Carrier Proteins blood, Female, Glomerulonephritis, IGA complications, Humans, Hypertension blood, Hypertension etiology, Kinetics, Male, Middle Aged, Antiporters, Erythrocytes metabolism, Glomerulonephritis, IGA blood, Lithium blood, Sodium blood
Abstract

The aim of this work was to analyze Na,Li countertransport activity in the erythrocytes from patients with IgA nephropathy, in relationship with their blood pressure status and lipid profile. Forty-nine patients (32 males, 17 females) with biopsy-proven IgA nephropathy and without significant impairment of renal function (serum creatinine less than or equal to 1.4 mg/dl) and 36 normal subjects (21 males, 15 females) were evaluated. Twenty-nine patients with IgA nephropathy were normotensive and 20 hypertensive (diastolic pressure greater than or equal to 95 mm Hg or treated by antihypertensive drugs). Na,Li countertransport was significantly higher in red cells from hypertensive than from normotensive patients (P = 0.002) and normal subjects (P = 0.0001), (values respectively 309 +/- 17; 241 +/- 12 and 211 +/- 11 mumol/liter RBC/hr); normotensive patients with IgA nephropathy did not differ from controls regarding the Na,Li countertransport rate. A multiple stepwise logistic regression analysis with blood pressure status as the dependent variable and Na,Li countertransport activity, age, serum creatinine, proteinuria, cholesterol, triglycerides, plasma potassium and time from onset as independent variables, indicated an independent significant association for Na,Li countertransport (P = 0.002) proteinuria (P = 0.006), plasma potassium (P = 0.006) and age (P = 0.029). Other tested variables were not independently related to blood pressure status. Hyperlipidemic patients (plasma total cholesterol concentration greater than 200 mg/dl and/or plasma triglycerides greater than 172 mg/dl) had an erythrocyte Na,Li countertransport activity significantly higher than normolipidemic (P = 0.005) and controls (P = 0.001) (values respectively 295 +/- 14; 226 +/- 12 and 211 +/- 11 mumol/liter RBC/hr).(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1991
Full Text
View/download PDF

50. Is there a link between cyclosporine A, altered cellular sodium transport, and arterial pressure in kidney transplant patients?

Author

Basolo B, Boero R, Guarena C, Forneris G, Formica M, Rollino C, Quarello F, Segoloni GP, and Piccoli G

Subjects
Adult, Azathioprine therapeutic use, Biological Transport, Blood Pressure, Erythrocytes metabolism, Female, Humans, Immunosuppression Therapy methods, Male, Potassium metabolism, Prednisone therapeutic use, Sodium-Potassium-Exchanging ATPase metabolism, Cyclosporins therapeutic use, Kidney Transplantation physiology, Sodium metabolism
Published
1991

Catalog

Books, media, physical & digital resources
See catalog results